BioSpace News Archive

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

Clinical activity includes one CR in a patient with a NPM1 mutation and one CR in a patient with a SETD2/RUNX1 mutation

61% Composite CR Rate in RARA-Positive Newly Diagnosed Unfit AML Patients, with Median Overall Survival of 18 Months Among Responders

Long-term follow-up data from the Phase III MURANO trial showed sustained progression-free survival with fixed-duration Venclexta plus Rituxan

9 of 14 Patients Showed Reduction in Tumor Size, Including Two Recently Reported Complete Responses

Data from ongoing Phase 1 expansion trial using nanoplasmid demonstrated an improvement in efficacy over standard plasmid and a potentially best-in-class safety profile

Autolus Therapeutics plc announced new data highlighting progress on its AUTO1 program, the company’s CAR T cell therapy being investigated in the ongoing ALLCAR Phase 1 study in relapsed / refractory adult B-Acute Lymphocytic Leukemia, during the American Society of Hematology All-Virtual Annual Meeting, held between December 5-8, 2020.

83% Overall Response Rate in Most Recent Evaluable Cohort of Heavily Pre-Treated Multiple Myeloma Patients

Updated Data Demonstrating Favorable Safety Profile and Encouraging Monotherapy Activity in BPDCN Presented During Oral Session

Kristen Pettit, M.D., of University of Michigan Presents Updated Interim Results from 49 Patients Show Reduction in Spleen Volume, Total Symptom Score